Patents by Inventor Iyassu Sebhat

Iyassu Sebhat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
    Publication number: 20110218174
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: October 22, 2009
    Publication date: September 8, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jianming Bao, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, Dariusz Wodka, Qun Dang, De Michael Chung, Tony S. Gibson, Hongjian Jiang, Daniel K. Cashion
  • NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
    Publication number: 20110195964
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: October 19, 2009
    Publication date: August 11, 2011
    Inventors: Qun Dang, De Michael Chung, Tony S. Gibson, Daniel K. Cashion, HongJian Jiang, Jianming Bao, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, Dariusz Wodka
  • NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
    Publication number: 20100081643
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: September 21, 2009
    Publication date: April 1, 2010
    Inventors: BRETT C. BOOKSER, Qun Dang, Tony S. Gibson, Hongjian Jiang, De Michael Chung, Jianming Bao, Jinlong Jiang, Andy Kassick, Ahmet Kekec, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, David Wilson, Dariusz Wodka
  • Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists
    Publication number: 20080051430
    Abstract: Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: July 13, 2005
    Publication date: February 28, 2008
    Inventors: Khaled Barakat, Liangqin Guo, Jian Liu, Ravi Nargund, Iyassu Sebhat, Zhixiong Ye
  • Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
    Publication number: 20060183904
    Abstract: Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: March 31, 2004
    Publication date: August 17, 2006
    Inventors: Liangqin Guo, Shuwen He, Tianying Jian, Jian Liu, Yingjie Lai, Ravi Nargund, Iyassu Sebhat, Feroze Ujjainwalla, Zhixiong Ye, Jonathan Young
  • Acylated piperidine derivatives as melanocortin-4 receptor agonists
    Publication number: 20060035935
    Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 16, 2006
    Inventors: Mark Goulet, Ravi Nargund, Iyassu Sebhat, Feroze Ujjainwalla, Thomas Walsh, Daniel Warner, Zhixiong Ye, Jonathan Young, Raman Bakshi
  • Substituted piperidines as melanocortin-4 receptor agonists
    Publication number: 20020137664
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Ravi P. Nargund, Brenda L. Palucki, Arthur A. Patchett, Iyassu Sebhat, Zhixiong Ye, Leonardus H.T. Van Der Ploeg
  • Substituted piperidines as melanocortin-4 receptor agonists
    Patent number: 6350760
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: February 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Ravi P. Nargund, Brenda L. Palucki, Arthur A. Patchett, Iyassu Sebhat, Zhixiong Ye, Leonardus H. T. Van Der Ploeg